ALLMedicine™ Hyperuricemia Center

Aug 6th, 2022 - Prevalence rates of hyperuricemia and gout are increasing. Clinical investigations of hyperuricemia-related risk factors aid in the early detection, prevention, and management of hyperuricemia and gout. Ongoing research is examining the associatio...

Aug 6th, 2022 - Over the last three decades, the mesoamerican region has seen an increase in the frequency of patients diagnosed with Chronic Kidney Disease of nontraditional causes (CKDnt) also known as Meso-American Nephropathy (MeN). A region with an increased...

Aug 5th, 2022 - Studies have shown that hyperuricemia (HUA) is an independent risk factor for all-cause death and residual kidney function loss in peritoneal dialysis (PD) patients. The control of blood uric acid (UA) is an important link to improve the prognosis...

Aug 5th, 2022 - Pre-eclampsia can be described as new-onset hypertension (blood pressure ≥140/90 mmHg) together with proteinuria (24-hr urinary protein ≥ 0.3 g) or any indication of end-organ damage after 20 weeks of gestation. Liver and kidney dysfunction, throm...

Aug 4th, 2022 - It is well-recognized that hyperuricemia is a common abnormality among individuals with metabolic syndrome. The objective of this study was to determine whether hyperuricemia is associated with the metabolically obese normal-weight (MONW) and meta...

Dec 22nd, 2021 - Gout is the most prevalent inflammatory arthritis in the Asia-Pacific region and worldwide. This clinical practice guideline (CPG) aims to provide recommendations based on systematically obtained evidence and values and preferences tailored to the...

Oct 31st, 2014 - Glycogen storage disease type I (GSD I) is a rare disease of variable clinical severity that primarily affects the liver and kidney. It is caused by deficient activity of the glucose 6-phosphatase enzyme (GSD Ia) or a deficiency in the microsomal ...

Jul 27th, 2022 - The pathogenesis of coronary heart disease is closely related to inflammation. IL-1 beta is an effective target for anti-inflammatory treatment of coronary heart disease. Allopurinol is a drug used for treating hyperuricemia and gout for many year...

Jul 27th, 2022 - With the development of China's economy, people's living standard have improved, and the dietary structure have changed. Metabolic diseases, such as hypertension, diabetes, hyperuricemia and obesity have gradually become an important health burden...

Jul 27th, 2022 - We identify all patients who had undergone primary total knee arthroplsty(TKA) from April 1, 2015, to March 30, 2016. Patients are grouped by uric acid level. The knee society score(KSS score) and the hospital for special surgery knee score (HSS s...

Jul 26th, 2022 - The aim of this study is to evaluate the effect of urate lowering therapy on improvement of steatosis in metabolic associated fatty liver disease (MAFLD) patients with hyperuricemia, by comparing two xanthine oxidase inhibitors allopurinol (100 mg...

Jul 20th, 2022 - Systemic lupus erythematosus (SLE) is a complex autoimmune disease that is characterized by multiple end-organ damage and predominantly affects premenopausal women. Cardiovascular disease is a major cause of morbidity and mortality in systemic lup...

Jul 13th, 2022 - Results from a randomized controlled trial conducted in China found low-dose benzbromarone to be more effective in lowering serum urate levels than low-dose febuxostat (Uloric), with a similar safety profile, in gout with renal uric acid underexcr...

Jan 25th, 2022 - Allopurinol treatment is not associated with increased mortality in patients with gout and chronic kidney disease even at 5 years after starting treatment, a study has found. Around 1 in 5 patients with gout also have chronic kidney disease, and p...

Nov 19th, 2021 - Patients with type 2 diabetes taking sodium-glucose cotransporter-2 (SGLT2) inhibitors saw a lower risk for gout, a Taiwanese cohort study found. Compared with patients taking DPP-4 inhibitors, those on an SGLT2 inhibitor had an 11% reduced risk f...

May 3rd, 2021 - The rolling submission of a new drug application (NDA) to the FDA for surufatinib for the treatment of patients with pancreatic and non-pancreatic neuroendocrine tumors (NETs) has been completed, according to an announcement from Hutchinson China ...

Mar 5th, 2021 - A majority of patients with advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC) obtained durable remissions with the ROS1 inhibitor entrectinib (Rozlytrek), according to an updated integrated analysis of three clinical t...